Is Avalon GloboCare Corp. (ALBT) a Buy, Sell, or Hold?
Avalon GloboCare Corp.
NASDAQ:ALBT
$0.2854 USD
$0.03 (11.4%)
- Volume
- 1.51M
- Average Volume
- 1.07M
- Market Capitalization
- $1.21M
- P/E Ratio
- -0.04
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $4.74
- Year Low
- $0.21
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.38
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Meng Li |
| Industry | Real Estate - Services |
| Sector | Real Estate |
| Current Symbol | ALBT |
| CUSIP | 05344R302 |
| CIK | 0001630212 |
| Web | https://www.avalon-globocare.com |
| Phone | 732 780 4400 |
| Currency | USD |
| Employees | 2 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.12 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.38 |
| Quick Ratio | 0.36 |
| Cash Ratio | 0.17 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | -3.45 |
| Cash Flow | -0.71 |
| Price / Cash Flow | -0.19 |
| Price / Book | 0.22 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.64 |
| Trailing P/E Ratio | -0.04 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-18.31M |
| Net Margin | 5579.32% |
| Pretax Margin | 5549.87% |
| Return on Equity | -835.03% |
| Return on Assets | -120.13% |
Financials Score
| AltmanZ Score | -13.25 |
| Piotroski Score | 2.00 |
| Working Capital | -2.77M |
| Total Assets | 16.25M |
| Ebit | -18.01M |
| Market Cap | 1.16M |
| Total Liabilities | 4.52M |
Poll Results
About Avalon GloboCare Corp. (NASDAQ:ALBT) Stock
Avalon GloboCare Corp., along with its affiliated entities, manages and holds commercial real estate assets across both the United States and China. The company's service portfolio encompasses medical consulting, offering diverse solutions such as conducting research studies, delivering executive education, disseminating daily online briefings for executives, providing customized expert advice, and supplying management and consulting expertise, particularly in the fields of immunotherapy and in facilitating second opinions or referrals. Key therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy, which has successfully completed its initial human clinical trial for B-cell lymphoblastic leukemia that has recurred or is resistant to treatment (R/R). Another promising candidate, AV ... A-011, also a CAR-T cell therapy, has advanced through preclinical laboratory evaluations and is currently in the IND-enabling process development phase to produce cGMP-grade cells. The company is additionally engaged in the development of an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is developing ACTEX, its proprietary clinical-grade, tissue-specific exosome. It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology, which includes leveraging this technology to create a hemofiltration device for treating Cytokine Storm. The firm also partners with Arbele Limited for the co-development of advanced, transposon-based CAR-T, CAR-NK, and various other multi-target immune effector cell therapies. A strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, aims to develop an S-layer vaccine against SARS-CoV-2 (the virus responsible for COVID-19), designed for intranasal or oral delivery. Beyond these initiatives, the company is progressing with Avalon Cell and Avalon Rehab, and actively advocates for standardization within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.
2026-07-15 09:00:00
FREEHOLD, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a technology innovation company developing products for high-growth health and technology markets, a developer of agentic artificial intelligence ("AI") software solutions, today announced plans to launch Beacon, a subscription-based Agentic Generative Search Optimization (GEO) platform designed to help small businesses improve their visibility across leading AI-powered search engines.
2026-06-16 09:00:00
FREEHOLD, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today provided an update on the Nevada POOL/PACT Holistic Health Reset program launched in collaboration with Saga Health and SpecialtyHealth, Inc. The four-month wellness initiative, which began in August 2025, was designed to support 50 first responders through a comprehensive health optimization program focused on improving metabolic, physical, and behavioral wellness outcomes.
Avalon GloboCare Appoints Seasoned AI and Finance Executive as Chief Financial Officer
2026-06-04 08:00:00
FREEHOLD, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today announced the appointment of Sam Knipper as Chief Financial Officer, effective June 1, 2026.
Avalon Quantum AI teams up with Caylent and Amazon Web Services on Agentic AI Platform Development
2026-04-21 08:30:00
AWS collaboration accelerates Catch-Up Phase 2 development to a fully autonomous Agentic AI Video Platform AWS collaboration accelerates Catch-Up Phase 2 development to a fully autonomous Agentic AI Video Platform
Frequently Asked Questions
-
What is the current Avalon GloboCare Corp. (ALBT) stock price?
-
Avalon GloboCare Corp.(NASDAQ:ALBT) stock price is $0.2854 in the last trading session. During the trading session, ALBT stock reached the peak price of $4.74 while $0.21 was the lowest point it dropped to. The percentage change in ALBT stock occurred in the recent session was 11.4% while the dollar amount for the price change in ALBT stock was $0.03.
-
ALBT's industry and sector of operation?
-
The NASDAQ listed ALBT is part of Real Estate - Services industry that operates in the broader Real Estate sector.
-
Who are the executives of ALBT?
-
Samuel J. Knipper | Chief Financial Officer
Luisa Ingargiola | Chief Strategy Officer
Meng Li | Interim CEO, COO & Secretary
|
| -
How many employees does ALBT have?
-
Number of ALBT employees currently stands at 2. ALBT operates from 4400 Route 9 South, Freehold, NJ 07728, US.
-
Link for ALBT official website?
-
Official Website of ALBT is: https://www.avalon-globocare.com
-
How do I contact ALBT?
-
ALBT could be contacted at phone #732 780 4400 and can also be accessed through its website. ALBT operates from 4400 Route 9 South, Freehold, NJ 07728, US.
-
How many shares of ALBT are traded daily?
-
The average number of ALBT shares traded daily for last 3 months was 1.07M.
-
What is the market cap of ALBT currently?
-
The market value of ALBT currently stands at $1.21M with its latest stock price at $0.2854